Vumon (teniposide) / BMS - LARVOL DELTA

Development and Validation of HPTLC Method for Estimation of Podophyllotoxin in Crude Extract, Isolated Podophyllotoxin and Marketed Mother Tincture of Podophyllum hexandrum Royle. (PubMed, Biomed Chromatogr) - "Podophyllotoxin, a naturally occurring cyclolignan isolated from the root and rhizomes of Podophyllum species is mainly used to synthesise etoposide and teniposide, which are used in various diseases. Similarly, the intraday precision ranged from 214.7 ± 19.55 to 443.6 ± 35.84, with a %RSD of 3.5-5.9. The chromatographic results suggest that the developed method can be used for the comparative identification of podophyllotoxin in the ethanolic extract, isolated podophyllotoxin and marketed mother tincture."

Journal

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=15 | Recruiting | Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Jun 2026

Enrollment open • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer

Strikingly Reduced Toxicities of Fotemustine-Based Chemotherapeutics Than High-Dose Methotrexate-Containing Regimens with Comparable Efficacy (ASH 2024) - "Therefore, this study increased the sample size, extended the follow-up time and set up a control group to analyze the efficacy and safety of fotemustine-containing regimens compared with HD-MTX-containing regimens in the treatment of newly diagnosed PCNSL patients.Methods : From April 2011 to December 2021, 114 patients with newly diagnosed PCNSL who received HD-MTX-containing regimens (HD-MTX plus cytarabine [HD-MA], rituximab, HD-MTX plus temozolomide [R-MT]) or fotemustine-containing regimens (fotemustine, teniposide plus dexamethasone [FTD], fotemustine, temozolomide plus dexamethasone [FVD], rituximab, fotemustine, pemetrexed plus dexamethasone [RFPD]) were retrospectively analyzed in this study...Neither the progression free survival (PFS) (P=0.783) nor the overall survival (OS) (P=0.918) exhibited remarkably difference between HD-MTX-containing group and fotemustine-containing group. Notably, we noted that patients treated with HD-MTX-containing regimens..."

Clinical • Anemia • Brain Cancer • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Melanoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Solid Tumor • Thrombocytopenia

Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Improved Prognosis for Advanced NK/T Cell Lymphoma (ASH 2024) - "Myeloablative conditioning regimens with either total body irradiation (TBI 10Gy fractionated, n=4)/teniposide (100mg/m2.d, 3 days)/fludarabine (30mg/m2.d, 5 days) or busulfan (0.8mg/kg q6h.d, 3 days, n=27)/ teniposide/fludarabine were applied...Graft-versus-host disease (GVHD) prophylaxis was with cyclosporine, short-term methotrexate and mycophenolate mofetil...P53 high expression and TP53 gene variants were highly associated with relapse after allo-HSCT. Our study has identified the profiles of HLH-related gene variants in advanced NKTCL and found LYST gene variants is the most frequent one related to HLH."

IO biomarker • Metastases • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • Rare Diseases • T Cell Non-Hodgkin Lymphoma • Transplantation • CTPS1 • LAMP1 • PRF1 • STXBP2 • TP53 • UNC13D • XIAP

Teniposide combined with bevacizumab for the treatment of recurrent high-grade MGMT promoter unmethylated glioma: A single-center prospective study (ChiCTR) - P=N/A | N=20 | Not yet recruiting | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University

New trial • Brain Cancer • Glioma • Oncology • Solid Tumor • MGMT

Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report. (PubMed, Anticancer Drugs) - "As of June 2025, the patient has achieved a CR with a progression-free survival of 9 months before experiencing disease recurrence. This rare case of NF1-associated oligodendroglioma was managed with thiotepa, bevacizumab, teniposide, and tunlametinib, highlighting the potential of MEK inhibition in NF1-related gliomas."

Journal • Brain Cancer • Genetic Disorders • Glioma • Neurofibromatosis • Oligodendroglioma • Oncology • Solid Tumor • NF1

In silico Study of Novel Tryptanthrin-Based Topoisomerase Inhibitors. (PubMed, Med Chem) - "Our computational approach was successful in identifying ligands that are potentially potent topoisomerase inhibitors. These can be tested further using in vitro and in vivo analysis."

Journal • Oncology

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL (clinicaltrials.gov) - P2/3 | N=215 | Not yet recruiting | Sponsor: Huashan Hospital

New P2/3 trial • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Triggering mitotic catastrophe by podophyllotoxin induces apoptosis in oral squamous cell carcinoma. (PubMed, Arch Oral Biol) - "This study provides compelling evidence supporting the potential therapeutic significance of inducing MC-mediated apoptosis in OSCC. The results underscore the role of PPT and its derivatives, such as etoposide and teniposide, in targeting rapidly dividing cancer cells through interference with mitotic progression, offering insights into novel therapeutic strategies for oral cancer."

Journal • Ataxia • Head and Neck Cancer • Immunology • Metabolic Disorders • Movement Disorders • Oncology • Oral Cancer • Primary Immunodeficiency • Solid Tumor • Squamous Cell Carcinoma • ANXA5 • BAX • CCNB1 • CHEK2

Management of Primary CNS Lymphoma: Young and Old (SOHO 2025) - "HD-MTX is typically administered every 10 to 21 days and is often combined with alkylating agents (eg, procarbazine or temozolomide), with or without high-dose cytarabine (HD-AraC)...11 Another regimen evaluated in large prospective trials is R-MBVP (rituximab, MTX, carmustine, teniposide, methylprednisolone) followed by HD-AraC...16 Other recommended induction options are represented by the R-MT (rituximab, MTX, temozolomide) 17 or R-MPV (rituximab, MTX, procarbazine, vincristine) regimen...21–23 In the IELSG32 trial, 20 the combination of carmustine and thiotepa (BCNU-TT) achieved a 2-year PFS of 75%, while in the PRECIS trial, 15 the TBC regimen (thiotepa, busulfan, cyclophosphamide) resulted in a 2-year PFS of 86%...30 Lenalidomide has shown promising results as a single-agent maintenance therapy after induction chemotherapy in this setting...WBRT and a maintenance strategy with oral drugs remain valid options for patients who are not suitable candidates for..."

B Cell Lymphoma • Brain Cancer • CNS Lymphoma • CNS Tumor • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Teniposide Triggers DNA Repair Inhibition by Binding and Ubiquitination of Apurinic/Apyrimidinic Endonuclease 1 to Boost Oxidative DNA Damage for Lung Cancer Destruction. (PubMed, ACS Pharmacol Transl Sci) - "In summary, these data make a strong argument for the notion that Ten/VM-26-mediated inhibition of APEX1 contributes to DNA damage and thereby achieves favorable antilung cancer effects, wherein Ten/VM-26 could down-regulate APEX1 by binding and ubiquitination. The current study presents a critical target and mechanism for Ten/VM-26-mediated antilung cancer therapy."

Journal • Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • APEX1

A single-center, single-arm, open-label study on the treatment of newly diagnosed patients with central malignant germ cell tumors with teniposide injection combined with cisplatin (ChiCTR) - P4 | N=100 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P4 trial • Germ Cell Tumors

VPX: Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University

New trial • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Rituximab in Primary Central Nervous system Lymphoma.nA randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup study (ANZCTR) - P3 | N=80 | Completed | Sponsor: HOVON | Active, not recruiting ➔ Completed

Trial completion • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • CD20

STRIKINGLY REDUCED TOXICITIES OF FOTEMUSTINE-BASED CHEMOTHERAPEUTICS THAN HIGH-DOSE METHOTREXATE-CONTAINING REGIMENS WITH COMPARABLE EFFICACY (ICML 2025) - " From April 2011 to December 2021, 114 patients with newly diagnosed PCNSL who received HD-MTX-containing regimens (HD-MTX plus cytarabine [HD-MA], rituximab, HD-MTX plus temozolomide [R-MT]) or fotemustine-containing regimens (fotemustine, teniposide plus dexamethasone [FTD], fotemustine, temozolomide plus dexamethasone [FVD], rituximab, fotemustine, pemetrexed plus dexamethasone [RFPD]) were retrospectively analyzed in this study. Fotemustine-based chemotherapeutics conferred a safer effect on newly-diagnosed PCNSL patients compared with HD-MTX-containing regimens together with comparable efficiency."

Clinical • CNS Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma

PTTD BRIDGING REGIMEN FACILITATES LOW-NEUROTOXICITY CAR-T THERAPY IN MULTIPLY RELAPSED CENTRAL NERVOUS SYSTEM LYMPHOMA: A PRELIMINARY EXPLORATORY STUDY (EHA 2025) - "The PTTD regimen (pemetrexed 500 mg/m² D1, teniposide 50 mg/m² D1-3, temozolomide 150 mg/m² D1-7, dexamethasone 40 mg D1-4) was administered every 21 days (median 2 cycles). This novel quadruple-agent bridging protocol demonstrates three critical advances in R/R CNSL management:Rapid cytoreduction (94% tumor burden reduction) permitting timely CAR-T administration; Abrogation of CAR-T neurotoxicity (0% ICANS vs 22% in ELARA CNSL cohort); Durable remission achievement (83% CMR) in transplant/CAR-T-refractory patients.All patients who used the PTTD regimen did not experience severe adverse reactions and were well-tolerated, which did not affect the collection of autologous stem cells. Subsequently, they were all bridged to CART cell therapy, and the safety and efficacy were confirmed.While limited by sample size, these findings establish PTTD as a transformative bridging strategy, with an expanded 30-patient cohort actively accruing."

CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology

Combination therapy targeting genomic and signal transduction vulnerabilities in epithelioid hemangioendothelioma (AACR 2025) - "Because most EHE cells contain either the TAZ-CAMTA1 or YAP-TFE3 fusion proteins that activate a transcriptome that promotes several hallmarks of cancer, targeting the main way the fusions interact with DNA could mitigate these effects. Previous studies investigating the use of monotherapies to target cells expressing the fusion proteins show limited effectiveness. However, targeting both the interaction of the fusion proteins' ability to interact with DNA as well as an important pathway for EHE cells, such as the PI3K pathway, could lead to a greater effectiveness in decreasing EHE tumor progression."

Combination therapy • Liposarcoma • Oncology • Sarcoma • Solid Tumor • CAMTA1 • TAFAZZIN • TFE3

Antitumor and immunomodulatory activities of diphyllin and its derivatives. (PubMed, Bioorg Med Chem) - "The structurally related aryltetralin lignan, podophyllotoxin, has served as a lead compound for both etoposide and teniposide, which have been developed as effective anticancer agents. In the present review, the role of V-ATPase in cancer immunotherapy and the structure-activity relationships (SARs) of diphyllin and its cytotoxic and V-ATPase inhibitory activities and the mechanisms of action are discussed. Also, the promise of diphyllin and its derivatives in the development of new adjuvants for cancer immunotherapies has been proposed."

Journal • Review • Oncology

Differences in transcriptome characteristics and drug repositioning of Alzheimer's disease according to sex. (PubMed, Neurobiol Dis) - "The characteristics of the transcriptome in peripheral blood and single-cell transcriptome in the prefrontal cortex exhibit significant differences between male and female patients with AD, which providing a basis for future sex stratified treatment of AD."

Journal • Alzheimer's Disease • CNS Disorders • Solid Tumor • BASP1 • TNS1

Bioinformatics screened of biomarkers for the prognosis of hepatocellular carcinoma. (PubMed, Cancer Biomark) - "Hub genes were enriched in various cell types. Trametinib, selumetinib, RDEA119, and teniposide were identified as potential drugs for LIHC treatment.ConclusionCDC20, TOP2A, CDK1, CAT, TAT, and FTCD may contribute to LIHC development and serve as novel prognostic biomarkers."

Biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • CDC20 • CDK1 • FTCD • TOP2A

SAFETY AND EFFICACY OF ALLO-HSCT WITH TENIPOSIDE CONTAINING CONDITIONING REGIMEN FOR PATIENTS WITH NK/T CELL LYMPHOMA (EBMT 2025) - "Background: This study aims to evaluate the safety and efficacy of allo-HSCT with etoposide(VM26)conditioning regimen in patients with NK/TCL. Allo-HSCT with a VM26 conditioning regimen demonstrates good safety in patients with NK/TCL. Compared to the non-VM26 group,the VM26 group showed a shorter time to remission in CNS-L and a higher rate of remission according to PET-CT assessment.There were no significant differences observed in OS,relapse rates, aGVHD and viral infections."

Clinical • Acute Graft versus Host Disease • Alopecia • Bone Marrow Transplantation • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

A prospective, single-center, single-arm clinical study evaluating the efficacy and safety of teniposide combined with RCHOP in newly diagnosed diffuse large B-cell lymphoma patients with high risk of central nervous system relapse (ChiCTR) - P=N/A | N=47 | Not yet recruiting | Sponsor: The first affiliated hospital Zhejiang University school of medicine; The first affiliated hospital Zhejiang University school of medicine

New trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD5

AMPK in Chemoradiotherapy-Induced Oral Mucositis. (PubMed, J Oral Pathol Med) - "AMPK emerges as a crucial regulator in OM post radiotherapy and chemotherapy, implicating sister chromatid separation, where DCs may play a pivotal role. Aloisine and Teniposide appear promising for OM prevention or treatment associated with these treatments."

Journal • Mucositis • Oncology • Stomatitis • AMPK • PRKAA2

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors. (PubMed, Biochim Biophys Acta Mol Basis Dis) - "Among those 147 drugs we found doxorubicin, daunorubicin, epirubicin, valrubicin, teniposide, afatinib, carmustine, vincristine, panobinostat, and vorinostat to have increased toxicity to cancer cells expressing the rapid NAT2 allele. Additionally, we report NAT2-mediated acetylation of idarubicin, daunorubicin, doxorubicin, vorinostat, and CUDC-101. These findings have implications for pharmacogenomics and cancer precision medicine using conventional chemotherapeutic drugs, as improving their efficacy and safety may affect >4 million cancer patients worldwide that receive these drugs as standard of care."

Journal • Oncology • NAT2